Skip to main content

Mild Cognitive Impairment (MCI)

9
Pipeline Programs
19
Companies
14
Clinical Trials
6 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
5
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
1100%
+ 21 programs with unclassified modality

Competitive Landscape

18 companies ranked by most advanced pipeline stage

Angeles Therapeutics
Angeles TherapeuticsCA - Los Angeles
3 programs
1
1
EscitalopramPhase 41 trial
Tadalafil 5 mgPhase 21 trial
Wearable Sensor for Early Detection and Monitoring of Cognitive DeclineN/A
Active Trials
NCT07882901Not Yet Recruiting44Est. Feb 2027
NCT01902004Completed115Est. Jan 2019
Prevail Therapeutics
1 program
1
DonanemabPhase 3Monoclonal Antibody
Biocorp
BiocorpFrance - Issoire
2 programs
1
XPro1595Phase 2
transcranial electric stimulationN/A
Risen Pharma Tech
Risen Pharma TechChina - Shanghai
1 program
1
RP902Phase 21 trial
Active Trials
NCT07579884Recruiting360Est. May 2031
INmune Bio
INmune BioFL - Boca Raton
1 program
1
XPro1595Phase 21 trial
Active Trials
NCT05321498Withdrawn0Est. Oct 2023
Neurim Pharmaceuticals
Neurim PharmaceuticalsIsrael - Tel Aviv
1 program
1
melatoninPhase 21 trial
Active Trials
NCT00544791Unknown50Est. Oct 2010
CuraSen Therapeutics
CuraSen TherapeuticsCA - San Carlos
1 program
1
CST-2032, matching placebo for CST-2032, CST-107Phase 11 trial
Active Trials
NCT05033912Withdrawn0Est. May 2022
Labcorp
LabcorpBURLINGTON, NC
1 program
1
Gamma- GlutamylcysteinePhase 11 trial
Active Trials
NCT07583251Recruiting9Est. Feb 2027
Innovation Pharmaceuticals
2 programs
RICORDO-DTxN/A
Remote Digital Assessments for Cognitive DisordersN/A1 trial
Active Trials
NCT07883746Not Yet Recruiting60Est. Apr 2028
Design Therapeutics
1 program
Insole and ankle deviceN/A1 trial
Active Trials
NCT07127133Not Yet Recruiting150Est. Aug 2027
Design Pharmaceuticals
1 program
Insole and ankle deviceN/A
ETS
ETSMO - Rolla
1 program
RICORDON/A1 trial
Active Trials
NCT07064226Recruiting102Est. Sep 2027
Mission Therapeutics
Mission TherapeuticsUK - Cambridge
1 program
RICORDO-DTxN/A
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
RICORDO-DTxN/A1 trial
Active Trials
NCT06657274Recruiting60Est. Aug 2026
Soterix Medical
Soterix MedicalNJ - Woodbridge
1 program
Transcranial Alternating Current StimulationN/A1 trial
Active Trials
NCT06783283Recruiting20Est. Dec 2027
Novartis
NovartisBASEL, Switzerland
1 program
transcranial electric stimulationN/A1 trial
Active Trials
NCT07092839Completed15Est. Jul 2024
Sandoz
SandozAustria - Kundl
1 program
transcranial electric stimulationN/A
Colorado Therapeutics
Colorado TherapeuticsCO - Louisville
1 program
transcutaneous auricular vagus nerve stimulationN/A1 trial
Active Trials
NCT07424365Recruiting80Est. May 2028

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
Angeles TherapeuticsEscitalopram
Angeles TherapeuticsTadalafil 5 mg
Risen Pharma TechRP902
INmune BioXPro1595
Neurim Pharmaceuticalsmelatonin
LabcorpGamma- Glutamylcysteine
CuraSen TherapeuticsCST-2032, matching placebo for CST-2032, CST-107
Design TherapeuticsInsole and ankle device
Innovation PharmaceuticalsRemote Digital Assessments for Cognitive Disorders
ETSRICORDO
Colorado Therapeuticstranscutaneous auricular vagus nerve stimulation
Soterix MedicalTranscranial Alternating Current Stimulation
UNION therapeuticsRICORDO-DTx
Novartistranscranial electric stimulation

Clinical Trials (14)

Total enrollment: 1,065 patients across 14 trials

NCT01902004Angeles TherapeuticsEscitalopram

Brain Aging and Treatment Response in Geriatric Depression

Start: Oct 2013Est. completion: Jan 2019115 patients
Phase 4Completed
NCT07882901Angeles TherapeuticsTadalafil 5 mg

Effects of Tadalafil on Cognition and Cerebral Hemodynamics in Elderly Patients With Mild Cognitive Impairment

Start: Sep 2026Est. completion: Feb 202744 patients
Phase 2Not Yet Recruiting
NCT07579884Risen Pharma TechRP902

To Evaluate the Safety and Efficacy of RP902 Tablets

Start: Jul 2026Est. completion: May 2031360 patients
Phase 2Recruiting
NCT05321498INmune BioXPro1595

Study to Assess the Efficacy of XPro1595 in Patients With Mild Cognitive Impairment With Biomarkers of Inflammation

Start: Jun 2023Est. completion: Oct 20230
Phase 2Withdrawn
NCT00544791Neurim Pharmaceuticalsmelatonin

The Effect of Melatonin on Cognitive Function in Patients Diagnosed With Mild Cognitive Impairment

Start: Oct 2007Est. completion: Oct 201050 patients
Phase 2Unknown
NCT07583251LabcorpGamma- Glutamylcysteine

Safety And Tolerability Of Gamma Glutamylcysteine (GGC) Oral Supplementation In MCI Patients

Start: Aug 2026Est. completion: Feb 20279 patients
Phase 1Recruiting
NCT05033912CuraSen TherapeuticsCST-2032, matching placebo for CST-2032, CST-107

A Study of CST-2032 in Subjects With Cognitive Impairment

Start: Oct 2021Est. completion: May 20220
Phase 1Withdrawn
NCT07127133Design TherapeuticsInsole and ankle device

An Insole and Ankle Device for Monitoring Cognitive Decline in Individuals at Risk for Alzheimer's Disease and/or Alzheimer's Disease Related Dementias (AD/ADRD)

Start: Dec 2026Est. completion: Aug 2027150 patients
N/ANot Yet Recruiting
NCT07883746Innovation PharmaceuticalsRemote Digital Assessments for Cognitive Disorders

Remote Digital Assessments for Cognitive Disorders

Start: Nov 2026Est. completion: Apr 202860 patients
N/ANot Yet Recruiting
NCT07064226ETSRICORDO

Validation of a Digital Intervention to Rehabilitate Cognitive Resources

Start: Oct 2025Est. completion: Sep 2027102 patients
N/ARecruiting
NCT07424365Colorado Therapeuticstranscutaneous auricular vagus nerve stimulation

Study to Investigate Vagus Nerve Stimulation to Augment Executive Function in Healthy and Cognitively Impaired Populations

Start: May 2025Est. completion: May 202880 patients
N/ARecruiting
NCT06783283Soterix MedicalTranscranial Alternating Current Stimulation

TACS to Engage Theta-Gamma Coupling and Enhance Working Memory in Patients With MCI (tACS-MCI)

Start: Jan 2025Est. completion: Dec 202720 patients
N/ARecruiting
NCT06657274UNION therapeuticsRICORDO-DTx

EARLY-COGN^3 - Smart Digital Solutions for EARLY Treatment of COGnitive Disability: a Neuropsychological, Neurophysiological and Neurobiological Perspective in Chronic Neurological Diseases - PNRR-MCNT2-2023-12377069

Start: Dec 2024Est. completion: Aug 202660 patients
N/ARecruiting
NCT07092839Novartistranscranial electric stimulation

Non-invasive Deep Brain Stimulation to Enhance Motor Skill Acquisition in Individuals With Mild Cognitive Impairment

Start: Jun 2021Est. completion: Jul 202415 patients
N/ACompleted

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
6 actively recruiting trials targeting 1,065 patients
19 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.